Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

[62] Trastuzumab contains an immunoglobulin G1 Fc region that may bind to receptors on peripheral blood mononuclear cells, natural killer cells, and activated T cells, which can activate antibody ...